C. Minichsdorfer

发表

Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18

M. Gnant, F. Fitzal, C. Singer, 2022, ESMO open.

Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients

G. Prager, T. Winder, A. Siebenhüner, 2020, Journal of clinical medicine.

Long-term endurance training increases serum cathepsin S levels in healthy female subjects

B. Litschauer, M. Sponder, M. Fritzer-Szekeres, 2018, Irish Journal of Medical Science (1971 -).

Autocrine amplification loop in statin‐induced apoptosis of human melanoma cells

M. Hohenegger, C. Minichsdorfer, 2009, British journal of pharmacology.

DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma

M. Preusser, T. Melchardt, T. Fuereder, 2022, Journal for ImmunoTherapy of Cancer.

Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer

J. Pammer, H. Fuchs, T. Fuereder, 2018, Medical Oncology.

Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells

M. Hohenegger, C. Minichsdorfer, C. Wasinger, 2015, Melanoma research.

Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy

T. Fuereder, M. Schmidinger, A. Gleiss, 2022, Annals of medicine.

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

T. Szekeres, Z. Bago-Horvath, M. Preusser, 2022, Nature Medicine.

Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study.

C. Czerny, M. Mittlboeck, T. Fuereder, 2021, Oral oncology.

Autocrine secretion of 15d‐PGJ2 mediates simvastatin‐induced apoptotic burst in human metastatic melanoma cells

M. Hohenegger, M. Zellner, C. Höller, 2014, British journal of pharmacology.

Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment?

R. Bartsch, C. Kolberg-Liedtke, C. Minichsdorfer, 2020, The Lancet. Oncology.

Expectations and perception of cancer treatment goals in previously untreated patients. The EXPECT trial

R. Bartsch, M. Kirschbaum, A. Berghoff, 2020, Supportive Care in Cancer.

DNA methylation transcriptionally regulates the putative tumor cell growth suppressor ZNF677 in non-small cell lung cancers

G. Lang, B. Döme, W. Klepetko, 2014, Oncotarget.

Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non–Small Cell Lung Cancers

Christoph C Zielinski, Walter Klepetko, Balazs Döme, 2012, Clinical Cancer Research.

Systemic therapy for metastatic salivary gland tumors—challenges and novel concepts

C. Minichsdorfer, 2020, memo - Magazine of European Medical Oncology.

Adolescents and Young Adults (AYAs) With Initially Localized and Metastatic Bone Sarcomas: A Retrospective Single Center Analysis of Side Effect Management

T. Brodowicz, M. Raderer, M. Schmid, 2021, In Vivo.

Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.

C. Gridelli, F. Hirsch, V. Georgoulias, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports.

Michael Gnant, R. Bartsch, C. Zielinski, 2016, Clinical journal of oncology nursing.

SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment

G. Prager, Daniel Spies, C. Zielinski, 2018, Translational oncology.

PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients

C. Krall, C. Wagner, T. Fuereder, 2019, Front. Oncol..

165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial

C. Singer, J. Furtner, R. Bartsch, 2022, Annals of Oncology.

Impact of COVID‐19 lockdown on routine oncology versus emergency care at a high volume cancer centre

M. Preusser, A. Laggner, R. Bartsch, 2021, European journal of clinical investigation.

280P Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial

M. Preusser, C. Singer, J. Furtner, 2021, Annals of Oncology.

281MO Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan: Secondary endpoint analysis of the prospective single-arm phase II TUXEDO-1 trial

C. Singer, J. Furtner, R. Bartsch, 2022, Annals of Oncology.

Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines

E. Tomasich, A. Otahal, C. Minichsdorfer, 2020, Scientific Reports.

HPV-associated cancers

C. Minichsdorfer, 2019, memo - Magazine of European Medical Oncology.

Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial

M. Preusser, G. Prager, H. Haslacher, 2023, Infectious Agents and Cancer.

Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines

E. Tomasich, A. Otahal, C. Minichsdorfer, 2020, Scientific Reports.